Preparing for and selecting an EHR

Article

The government is providing time-sensitive incentives to drive EHR adoption. There's a lot to learn, let's get started.

A Beginners Guide to Selecting an EHR

You've heard that EHR systems can improve patient care, streamline paper-based workflows, increase revenue and save time for you and your staff. And now the government is providing time-sensitive incentives to drive EHR adoption. However, the high costs, time and complexity of implementing an EHR can be intimidating. Not to mention the leap of faith and uncertainty that go with completely redesigning your office.

Welch Allyn EHR Prep-Select Services can help your practice manage the complexity and overcome the uncertainty. Our expert consultants and innovative online tools will guide you step by step , helping you ask all the right questions about how an EHR might impact your practice, find the right answers, then leverage the information to make the best decisions.

View a demo about the Welch Allyn EHR Prep-Select Service

See for yourself! Sign up for a no-obligation FREE consultation (a $295 value) with a Welch Allyn EHR Prep-Select consultant.

 

 
www.welchallyn.com

View Whitepaper

Video

 

Recent Videos
Sonia Jain, PhD, stated that depatuxizumab mafodotin, ABBV-221, and ABBV-321 were 3 of the most prominent ADCs in EGFR-amplified glioblastoma.
2 experts are featured in this series.
2 experts are featured in this series.
Skin toxicities are common with targeted therapies for GI malignancies but can be remedied by preventative measures and a collaboration with dermatology.
Computational models help researchers anticipate how ADCs may behave in later lines of development, while they are still in the early stages.
2 experts are featured in this series.
ADC payloads with high levels of potency can sometimes lead to higher levels of toxicity, which can eliminate the therapeutic window for patients with cancer.
According to Greg Thurber, PhD, target-mediated uptake is the biggest driver of efficacy for antibody-drug conjugates as a cancer treatment.
Related Content